,Symbol,Name,description__profile,ceo__profile,industry__profile,price__profile,currency__profile,mktCap__profile,image__profile,volAvg__profile,pe__quote,change__quote,volume__quote,ebitda__income_statement,netIncome__income_statement,annual_earnings,quaterly_earnings,eps__income_statement,epsdiluted__income_statement,totalAssets__balance_sheet_statement,totalCurrentAssets__balance_sheet_statement,cashAndShortTermInvestments__balance_sheet_statement,totalLiabilities__balance_sheet_statement,netReceivables__balance_sheet_statement,longTermInvestments__balance_sheet_statement,totalCurrentLiabilities__balance_sheet_statement,cashAndCashEquivalents__balance_sheet_statement,freeCashFlow__cash_flow_statement,growthEBITDA__income_statement_growth,growthNetIncome__income_statement_growth,growthEPS__income_statement_growth,dividend__historical-price-full/stock_dividend,date__historical-price-full/stock_dividend,derived__netIncomeMargin,derived__debtRatio
0,KALA,Kala Pharmaceuticals Inc. Common Stock,"Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.",Mr. Mark T. Iwicki,Drug Manufacturers - Specialty & Generic,6.81,USD,31395053,https://images.financialmodelingprep.com/symbol/KALA.png,35773,-0.58,-0.01,31761,-36082000,-42199000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -42.2}, {'period': '2022', 'revenue': 3890.0, 'unit': 'K', 'net_profit': -223.0}, {'period': '2021', 'revenue': 11.24, 'unit': 'M', 'net_profit': -152.3}, {'period': '2020', 'revenue': 6.36, 'unit': 'M', 'net_profit': -112.0}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.95}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.58}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.81}, {'period': ""Q4 '23"", 'revenue': 0.07, 'unit': 'M', 'net_profit': -8.63}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.7}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.41}]",-17.35,-17.35,55949000,52870000,50895000,48445000,236000,301000,8346000,50895000,-28537000,0.01673206889034227,-188.23318385650225,-114.66666666666669,__nan__,__nan__,__nan__,0.8658778530447372
1,KALU,Kaiser Aluminum Corporation Common Stock,"Kaiser Aluminum Corporation engages in manufacture and sale of semi-fabricated specialty aluminum mill products in the United States and internationally. The company offers rolled, extruded, and drawn aluminum products used for aerospace and defense, aluminum beverage and food packaging, automotive and general engineering products. The company's automotive extrusions include extruded aluminum products for structural components, crash management systems, anti-lock braking systems, and drawn tubes for drive shafts, as well as offers fabrication services, including sawing and cutting to length. Its packaging products consist of bare and coated 3000- and 5000-series alloy aluminum coil used for beverage and food packaging industry; and Its general engineering products comprise alloy plate, sheet, rod, bar, tube, wire, and standard extrusion shapes used in various applications, including the production of military vehicles, ordnances, semiconductor manufacturing cells, electronic devices, after-market motor sport parts, tooling plates, parts for machinery and equipment, bolts, screws, nails, and rivets. In addition, it offers rerolled, extruded, drawn, and cast billet aluminum products for industrial end uses. It sells its products directly to customers through sales personnel located in the United States, Canada, Western Europe, and China, as well as through independent sales agents in other regions of Asia, Latin America, and the Middle East. The company was founded in 1946 and is headquartered in Foothill Ranch, California.",Mr. Keith A. Harvey,Aluminum,70.21,USD,1129538480,https://images.financialmodelingprep.com/symbol/KALU.png,138908,24.21,-0.17,95855,211800000,47200000,"[{'period': '2023', 'revenue': 3090.0, 'unit': 'M', 'net_profit': 47.2}, {'period': '2022', 'revenue': 3430.0, 'unit': 'M', 'net_profit': -29.6}, {'period': '2021', 'revenue': 2620.0, 'unit': 'M', 'net_profit': -18.5}, {'period': '2020', 'revenue': 1170.0, 'unit': 'M', 'net_profit': 28.8}]","[{'period': ""Q3 '24"", 'revenue': 747.7, 'unit': 'M', 'net_profit': 12.0}, {'period': ""Q2 '24"", 'revenue': 773.4, 'unit': 'M', 'net_profit': 3.1}, {'period': ""Q1 '24"", 'revenue': 737.5, 'unit': 'M', 'net_profit': 24.6}, {'period': ""Q4 '23"", 'revenue': 721.7, 'unit': 'M', 'net_profit': 7.6}, {'period': ""Q3 '23"", 'revenue': 743.6, 'unit': 'M', 'net_profit': 5.4}, {'period': ""Q2 '23"", 'revenue': 814.1, 'unit': 'M', 'net_profit': 18.3}]",2.95,2.92,2267400000,990200000,82400000,1615200000,396100000,0,370000000,82400000,68700000,0.6106463878326996,2.5945945945945947,2.586021505376344,"[0.77, 0.18]","['2024-10-25', '2007-07-25']",__nan__,0.7123577666049219
2,KALV,KalVista Pharmaceuticals Inc. Common Stock,"KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.",Mr. Benjamin L. Palleiko,Biotechnology,7.85,USD,387931300,https://images.financialmodelingprep.com/symbol/KALV.png,348663,-2.13,-0.39,418387,-134280000,-126644000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -126.64}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -74.85}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -68.51}, {'period': '2021', 'revenue': 12.69, 'unit': 'M', 'net_profit': -44.49}]","[{'period': ""Q2 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -42.27}, {'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -40.44}, {'period': ""Q4 '24"", 'revenue': 1.21, 'unit': 'M', 'net_profit': -44.65}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.03}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.65}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -25.32}]",-3.44,-3.44,235404000,225690000,210401000,28822000,10871000,0,22807000,31789000,-89674000,-0.45790130828945225,-0.691902796147115,-0.28358208955223874,__nan__,__nan__,__nan__,0.12243632223751508
